BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G. Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. Clin Pharmacol Ther 2019;106:148-63. [PMID: 30107040 DOI: 10.1002/cpt.1211] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Torres C, Dumas S, Palacio-Castañeda V, Descroix S, Brock R, Verdurmen WPR. A Computational Investigation of In Vivo Cytosolic Protein Delivery for Cancer Therapy. Pharmaceutics 2021;13:562. [PMID: 33921165 DOI: 10.3390/pharmaceutics13040562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hempel G. How physiologically based pharmacokinetic models should be improved for drug development. Future Med Chem 2020;12:1107-9. [PMID: 32349520 DOI: 10.4155/fmc-2020-0074] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Ahmed S, Ellis M, Li H, Pallucchini L, Stein AM. Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems. J Pharmacokinet Pharmacodyn 2019;46:287-304. [PMID: 31037615 DOI: 10.1007/s10928-019-09638-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
4 Yates JWT, Byrne H, Chapman SC, Chen T, Cucurull-Sanchez L, Delgado-SanMartin J, Di Veroli G, Dovedi SJ, Dunlop C, Jena R, Jodrell D, Martin E, Mercier F, Ramos-Montoya A, Struemper H, Vicini P. Opportunities for Quantitative Translational Modeling in Oncology. Clin Pharmacol Ther 2020;108:447-57. [PMID: 32569424 DOI: 10.1002/cpt.1963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
5 Shah JV, Gonda A, Pemmaraju R, Subash A, Bobadilla Mendez C, Berger M, Zhao X, He S, Riman RE, Tan MC, Pierce MC, Moghe PV, Ganapathy V. Shortwave Infrared-Emitting Theranostics for Breast Cancer Therapy Response Monitoring. Front Mol Biosci 2020;7:569415. [PMID: 33134314 DOI: 10.3389/fmolb.2020.569415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Molenaar-Kuijsten L, van Meekeren M, Verheijen RB, Bovée JVMG, Fiocco M, Thijssen B, Rosing H, Huitema ADR, Miah AB, Gelderblom H, Haas RLM, Steeghs N. Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma. Cancers (Basel) 2021;13:5780. [PMID: 34830931 DOI: 10.3390/cancers13225780] [Reference Citation Analysis]
7 Nessler I, Menezes B, Thurber GM. Key metrics to expanding the pipeline of successful antibody-drug conjugates. Trends Pharmacol Sci 2021;42:803-12. [PMID: 34456094 DOI: 10.1016/j.tips.2021.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Awad NS, Paul V, AlSawaftah NM, Ter Haar G, Allen TM, Pitt WG, Husseini GA. Ultrasound-Responsive Nanocarriers in Cancer Treatment: A Review. ACS Pharmacol Transl Sci 2021;4:589-612. [PMID: 33860189 DOI: 10.1021/acsptsci.0c00212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Li Y, Li C, Tu Y, Tao J, Liu P, Xu H, Tang Y, Gu Y. In vivo assessing colitis severity by topical administration of fluorescent probe against neutrophils. Talanta 2021;233:122519. [PMID: 34215134 DOI: 10.1016/j.talanta.2021.122519] [Reference Citation Analysis]
10 Bhushan A, Gonsalves A, Menon JU. Current State of Breast Cancer Diagnosis, Treatment, and Theranostics. Pharmaceutics 2021;13:723. [PMID: 34069059 DOI: 10.3390/pharmaceutics13050723] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Terracciano R, Carcamo-Bahena Y, Butler EB, Demarchi D, Grattoni A, Filgueira CS. Hyaluronate-Thiol Passivation Enhances Gold Nanoparticle Peritumoral Distribution When Administered Intratumorally in Lung Cancer. Biomedicines 2021;9:1561. [PMID: 34829790 DOI: 10.3390/biomedicines9111561] [Reference Citation Analysis]
12 Deonarain MP, Xue Q. Tackling solid tumour therapy with small-format drug conjugates. Antib Ther 2020;3:237-45. [PMID: 33928231 DOI: 10.1093/abt/tbaa024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Fertal SA, Poterala JE, Ponik SM, Wisinski KB. Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer. Cancers 2022;14:1238. [DOI: 10.3390/cancers14051238] [Reference Citation Analysis]
14 Deonarain MP, Yahioglu G. Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy. Expert Opin Drug Discov 2021;16:613-24. [PMID: 33275475 DOI: 10.1080/17460441.2021.1858050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 AlSawaftah N, Pitt WG, Husseini GA. Dual-Targeting and Stimuli-Triggered Liposomal Drug Delivery in Cancer Treatment. ACS Pharmacol Transl Sci 2021;4:1028-49. [PMID: 34151199 DOI: 10.1021/acsptsci.1c00066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Chua CYX, Ho J, Susnjar A, Lolli G, Di Trani N, Pesaresi F, Zhang M, Nance E, Grattoni A. Intratumoral Nanofluidic System for Enhancing Tumor Biodistribution of Agonist CD40 Antibody. Adv Therap 2020;3:2000055. [DOI: 10.1002/adtp.202000055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
17 Tang Y, Parag-Sharma K, Amelio AL, Cao Y. A Bioluminescence Resonance Energy Transfer-Based Approach for Determining Antibody-Receptor Occupancy In Vivo. iScience 2019;15:439-51. [PMID: 31121469 DOI: 10.1016/j.isci.2019.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Kumar D, Mishra A, Lisok A, Kureshi R, Shelake S, Plyku D, Sen R, Doucet M, De Silva RA, Mease RC, Forde PM, Jaffee EM, Desai P, Ganguly S, Gabrielson E, Vaidya D, Spangler JB, Nimmagadda S. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proc Natl Acad Sci U S A 2021;118:e2107982118. [PMID: 34508005 DOI: 10.1073/pnas.2107982118] [Reference Citation Analysis]
19 Solans BP, Garrido MJ, Trocóniz IF. Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology. Clin Pharmacokinet 2020;59:123-35. [PMID: 31654368 DOI: 10.1007/s40262-019-00828-3] [Reference Citation Analysis]
20 Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater 2021;6:351-70. [DOI: 10.1038/s41578-020-00269-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 21.0] [Reference Citation Analysis]
21 Tang Y, Cao Y. Modeling the dynamics of antibody-target binding in living tumors. Sci Rep 2020;10:16764. [PMID: 33028895 DOI: 10.1038/s41598-020-73711-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
22 Bailly C, Chalopin B, Gouard S, Carlier T, Saëc PR, Marionneau-Lambot S, Moreau P, Touzeau C, Kraeber-Bodere F, Bodet-Milin C, Chérel M. ImmunoPET in Multiple Myeloma-What? So What? Now What? Cancers (Basel) 2020;12:E1467. [PMID: 32512883 DOI: 10.3390/cancers12061467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
23 Tang Y, Cao Y. Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. Pharmaceutics 2021;13:422. [PMID: 33800976 DOI: 10.3390/pharmaceutics13030422] [Reference Citation Analysis]
24 Lu G, Nishio N, van den Berg NS, Martin BA, Fakurnejad S, van Keulen S, Colevas AD, Thurber GM, Rosenthal EL. Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates. Nat Commun 2020;11:5667. [PMID: 33168818 DOI: 10.1038/s41467-020-19498-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
25 Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet 2019;58:835-57. [PMID: 30815848 DOI: 10.1007/s40262-019-00748-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 38.5] [Reference Citation Analysis]
26 Xu F, Xi H, Liao M, Zhang Y, Ma H, Wu M, Xue Q, Sun H, Zhang Y, Xia Y. Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy. Cancer Chemother Pharmacol. [DOI: 10.1007/s00280-021-04386-z] [Reference Citation Analysis]
27 Morcos PN, Li J, Hosseini I, Li CC. Quantitative Clinical Pharmacology of T-Cell Engaging Bispecifics: Current Perspectives and Opportunities. Clin Transl Sci 2021;14:75-85. [PMID: 32882099 DOI: 10.1111/cts.12877] [Reference Citation Analysis]
28 van de Stadt EA, Yaqub M, Schuit RC, Bartelink IH, Leeuwerik AF, Schwarte LA, de Langen AJ, Hendrikse H, Bahce I. Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients. Diagnostics 2022;12:883. [DOI: 10.3390/diagnostics12040883] [Reference Citation Analysis]
29 Menezes B, Cilliers C, Wessler T, Thurber GM, Linderman JJ. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens. AAPS J 2020;22:29. [PMID: 31942650 DOI: 10.1208/s12248-019-0391-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
30 Nessler I, Cilliers C, Thurber GM. Practical Guide for Quantification of In Vivo Degradation Rates for Therapeutic Proteins with Single-Cell Resolution Using Fluorescence Ratio Imaging. Pharmaceutics 2020;12:E132. [PMID: 32033318 DOI: 10.3390/pharmaceutics12020132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Palacio-Castañeda V, Dumas S, Albrecht P, Wijgers TJ, Descroix S, Verdurmen WPR. A Hybrid In Silico and Tumor-on-a-Chip Approach to Model Targeted Protein Behavior in 3D Microenvironments. Cancers (Basel) 2021;13:2461. [PMID: 34070171 DOI: 10.3390/cancers13102461] [Reference Citation Analysis]